share_log

港股异动 | 基石药业-B(02616)涨超12% ROR1 ADC最新研究数据即将亮相ASCO 全球空间有望超百亿美元

Changes in Hong Kong stocks | Cornerstone Pharmaceutical-B (02616) rose more than 12%, ROR1 ADC's latest research data will soon be revealed, ASCO's global space is expected to exceed 10 billion US dollars

Zhitong Finance ·  May 16 11:39

The Zhitong Finance App learned that Cornerstone Pharmaceutical-B (02616) rose by more than 12%. As of press release, it had risen 12.73% to HK$1.24, with a turnover of HK$2.7634 million.

According to the news, the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting will be held in Chicago from May 31 to June 4, US Eastern Time, in a combination of online and offline formats. The conference is one of the most important conferences in the field of global oncology. Among the 2024 ASCO ADC key clinical trials inventoried by Guosheng Securities, Cornerstone Pharmaceutical CS5001 treated patients with advanced solid tumors and lymphoma, phase 1a/1b, and the first global multi-center human study.

Southwest Securities previously stated that CS5001 is a ROR1 ADC. Only three ROR1 ADCs are in the clinical phase. The first two models were acquired by MSD and Boehringer Ingelheim (BI) at a high price of $2.75 billion and $1.43 billion, respectively. The reason for this is that ROR1 is a tumor embryonic protein, which is highly expressed in various solid tumors and hematomas, such as non-small cell lung cancer, leukemia, lymphoma, etc. The global patient population is 3 million. Once the drug is developed, the space is expected to reach tens of billions of dollars.

The translation is provided by third-party software.


The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment